Ventria Bioscience Release: In Vivo Characterization of Optiferrin Recombinant Human Transferrin Demonstrates Functional Similarity to Serum-Derived Human Transferrin
12/13/2012 10:03:08 AM
FORT COLLINS, Colo.--(BUSINESS WIRE)--A study comparing the in vivo receptor-binding and iron transport characteristics of Ventria Bioscience’s Optiferrin™ recombinant human transferrin (rhTF) to native, serum-derived human transferrin (hTF) was published today in the journal BMC Biotechnology1. The results of the study show that Optiferrin is functionally comparable to purified human transferrin in its ability to bind to the transferrin receptor (TFR) and participate in TFR-mediated endocytosis, intracellular iron delivery, and processing in a variety of cultured mammalian and human cell lines. Optiferrin is produced by Ventria Bioscience using ExpressTec and sold commercially by InVitria, the bioreagents division of Ventria Bioscience, for use in cell culture applications. Ventria Bioscience is also pursuing a clinical development program for the protein.